ONWARD Medical Q3 2025 Update: Rising ARC-EX Adoption in the U.S.

ONWARD Medical N.V. has reported significant progress in Q3 2025 with the accelerated adoption of its ARC-EX system across the United States. The company sold 40 ARC-EX systems during the quarter, expanding its reach to over 50 clinics nationwide. This reflects a growing acceptance of its external spinal cord stimulation technology designed to aid people with movement disabilities.

In terms of regulatory progress, the ARC-EX system received the CE Mark certification, while the FDA approved an investigational device exemption for the ARC-IM system. This allows ONWARD to initiate a pivotal study on blood pressure instability post spinal cord injury.

Scientific advancement continues with publications in Nature and Nature Medicine on blood pressure regulation. Financially, ONWARD achieved a milestone, surpassing EUR 1 million in quarterly revenue for the first time.